Dr. Kamesh Ravichandran : Research Instructor

Institution: University of Colorado Denver- Anschutz Medical Campus
Department: SOM-BioChem&Molecular Genetics
Email:KAMESWARAN.RAVICHANDRAN@CUANSCHUTZ.EDU

Dr. Kamesh Ravichandran got his Ph.D. in Biochemistry in 2011 in the Department of Zoology, University of Madras. He is currently a Research Instructor in the Department of Biochemistry and Molecular Genetics, University of Colorado Denver. Dr. Ravichandran’s expertise is in small molecule drug discovery in cancer, autosomal dominant polycystic kidney disease (ADPKD) Onconephrology, and in acute kidney injury (AKI). Dr. Ravichandran has 10+ years of experience working with mice and rats, expertise in various modes of drug delivery, cell line, patient-derived tumor implantation, microsurgery, and ethical animal care. He is proficient in cell culture techniques of mammalian cells, primary cells, and murine embryonic stem cells, including differentiation assays and cell-based assays. Dr. Ravichandran is skilled in molecular techniques, including tissue histology, PCR, chromatin biology, gene editing, and protein expression analysis. He has served as a Co-Principal Investigator in Ionis Pharma sponsored grant to study Antisense Oligonucleotide (ASO) in various preclinical genetic models of autosomal dominant polycystic kidney disease (ADPKD) and served as key personnel in various NIH and Veteran Affairs (VA) grants. He was awarded an outstanding research scholar by the American Federation of Medical Research in 2014. Overall, he has twenty-four publications, and two invited reviews in leading international journals and out of which he has 15 first and co-first author publications. His publications were selected for the cover page in the high impact AACR journals Clinical Cancer Research and Cancer Prevention Research. Research Contributions: Autosomal Dominant Polycystic Kidney Disease (ADPKD): He initiated preclinical trials using second-generation mTOR inhibitors like PP242, mTOR Antisense Oligonucleotide (ASO) in various genetic models of ADPKD has resulted in NIH initiated clinical trials and out of which PP242 is in phase 1 clinical trial for solid tumors and lymphomas. Onconephrology: This invivo model is the most appreciated and widely used preclinical model in onconephrology to date. The project's outcome resulted in the characterization of the IL-33/CD4 T cell/CXCL-8 axis in AKI with and without cancer.